Acquisition by Capper Joseph H of 468 shares of Anika Therapeutics subject to Rule 16b-3

ANIK Stock  USD 17.35  0.20  1.14%   
About 64% of all Anika Therapeutics' institutional investors are looking to take a long position. The analysis of the overall investor sentiment regarding Anika Therapeutics suggests that some traders are interested. Anika Therapeutics' investing sentiment shows overall attitude of investors towards Anika Therapeutics.
  
Filed transaction by Anika Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Anika insider trading alert for acquisition of common stock by Capper Joseph H, Director, on 5th of June 2024. This event was filed by Anika Therapeutics with SEC on 2024-06-03. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Anika Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Anika Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Anika Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Anika Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Anika Therapeutics Fundamental Analysis

We analyze Anika Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anika Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anika Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Liabilities

Current Liabilities Comparative Analysis

Anika Therapeutics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Anika Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Anika Therapeutics stock to make a market-neutral strategy. Peer analysis of Anika Therapeutics could also be used in its relative valuation, which is a method of valuing Anika Therapeutics by comparing valuation metrics with similar companies.

Peers

Anika Therapeutics Related Equities

NPCENeuropace   5.67   
0%
100.0%
KIDSOrthopediatrics Corp   0.96   
0%
16.0%
AORTArtivion   0.20   
0%
3.0%
OFIXOrthofix Medical   0.16   
0%
2.0%
SRDXSurModics   0.30   
5.0%
0%
AXGNAxogen   0.82   
14.0%
0%
FNAParagon 28   0.87   
15.0%
0%
AVNSAvanos Medical   2.91   
51.0%
0%
CVRXCVRx   3.09   
54.0%
0%
SGHTSight Sciences   3.98   
70.0%
0%
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out Anika Therapeutics Hype Analysis, Anika Therapeutics Correlation and Anika Therapeutics Performance.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(6.64)
Revenue Per Share
11.139
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.04)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.